It is no coincidence that Farmindustria

[nurmohammadkhan]

(the Italian association of pharmaceutical companies) has underlined that “ The renaissance of biopharmaceutical research is coming from network innovation ” . Therefore, from the factories themselves, to the research and development laboratories, and then to the patients . Even in this last aspect, which is truly decisive, 4.0 is making its power felt, radically changing the way in which pharmaceutical companies interface with their consumers.

Again, “ collaboration ” is one of the decisive keywords. A collaboration that algeria phone data involves pharmaceutical companies, companies that deal more specifically with healthcare, but also – more generally – companies in the tech sector. A very broad know-how, which has a positive impact on the patient, who in turn becomes an active agent, provides feedback, communicates more easily with companies, institutions, intermediate bodies .

The goal is to go beyond the old perspective of pure drug administration, to embrace a “ beyond the pill ” perspective (literally, beyond the pill), which concerns the health and well-being of individuals in all respects and it is precisely here that the great theme of personalization comes into play, which we will return to shortly, but first let's start with the data.